Pembrolizumab for previously treated metastatic triple negative breast cancer [ID1246]
Discontinued
Reference number: GID-TA10295
As you will be aware, the Department for Health and Social Care has asked NICE to carry out a Single Technology Appraisal of pembrolizumab for previously treated oesophageal or gastro-oesophageal junction cancer.
Please note that the timelines for this appraisal have been revised and the appraisal is now anticipated to begin in mid-January 2019